The present disclosure relates to a construct or a vector for reprogramming stem cells, differentiated cells, or mixtures thereof into hemogenic and/or hematopoietic stem cell-like cells, wherein the construct or the vector encodes a peptide comprising a combination of two isolated or synthetic transcription factors, preferably at least three isolated or synthetic transcription factors. The disclosure also relates to a composition comprising said construct or vector, to a method for reprogramming or inducing a stem cell or a differentiated cell into hemogenic and/or hematopoietic stem cell-like cells comprising a step of transducing a cell with at least one of said vectors; to a induced hemogenic and/or hematopoietic stem cell-like cell obtained by said method; to a composition comprising said induced hemogenic and/or hematopoietic stem cell-like cell; and to a kit comprising at least one of the following components: the induced hemogenic and/or hematopoietic stem cell-like cell; the composition as described in any of the previous claims; the vector or the construct as disclosed; or mixtures thereof.

The present disclosure relates to compositions, vectors, constructs, cells and methods for the reprogramming of cells into natural killer (NK) cells or progenitors. In particular, it relates to a combination of transcription factors for the reprogramming of cells.

WO2022129542

Abstract

The present disclosure relates to compositions for reprogramming cells into conventional dendritic cells (cDC), particularly into cDC type 2 (hereinafter referred to as “cDC2” or “CD11b-positive dendritic cells”), methods and uses thereof. The present disclosure relates to the development of methods for making conventional dendritic cells with antigen presenting capacity from differentiated, multipotent or pluripotent stem cells by introducing and expressing isolated/synthetic transcription factors. More particularly, the disclosure provides methods for obtaining conventional dendritic cells (cDC), particularly cDC type 2 or CD11b-positive dendritic cells, by direct cell reprogramming with the surprisingly use of combinations of specific transcription factors.

WO-2021-105234

Abstract

The present disclosure relates to compositions, constructs and vectors for reprogramming cells into plasmacytoid dendritic cells or interferon type I-producing cells, methods and uses thereof. The present disclosure relates to the development of methods for making plasmacytoid dendritic cells or interferon type I-producing cells that promote antiviral and anti-tumoral immune responses from differentiated, multipotent or pluripotent stem cells by introducing and expressing isolated/synthetic transcription factors. More particularly, the disclosure provides methods for obtain plasmacytoid dendritic cells or interferon type I-producing cells by direct cellular reprogramming with the surprisingly use of combinations of specific transcription factors.

WO-2021-069672

Abstract

The present disclosure relates to compositions, nucleic acid constructs, methods and kits thereof for cell induction or reprogramming cells to the dendritic cell state or antigen presenting cell state, based, in part, on the surprisingly effect described herein of novel use and combinations of transcription factors that permit induction or reprogramming of differentiated or undifferentiated cells into dendritic cells or antigen presenting cells. Such compositions, nucleic acid constructs, methods and kits can be used for inducing dendritic cells in vitro, ex vivo, or in vivo, and these induced dendritic cells or antigen presenting cells can be used for immunotherapy applications.

WO-2018-185709

Patent transfered to start-up company Asgard Therapeutics AB

Abstract

The disclosure relates to the development of methods for making hematopoietic stem cells from differentiated cells by introducing and expressing transcription factors. More particularly, the disclosure provides methods for redirecting differentiated cells to a hematopoietic stem cell state or to a hemogenic endothelial cell state by direct programming with specific combinations of transcription factors.

WO2013116307